Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | +7.59% |
|
+12.58% | -12.37% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company appears to be poorly valued given its net asset value.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.37% | 403M | C | ||
+20.95% | 127B | B+ | ||
+23.00% | 116B | B+ | ||
+25.15% | 27.69B | B | ||
-19.75% | 19.62B | B+ | ||
-16.57% | 16.26B | A- | ||
-16.56% | 15.49B | B | ||
+11.19% | 14.81B | C+ | ||
-46.65% | 14.39B | A- | ||
+57.74% | 14.11B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LYEL Stock
- Ratings Lyell Immunopharma, Inc.